H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Apellis Pharmaceuticals to $87 from $75 and keeps a Buy rating on the shares. Syfovre won approval for the treatment of geographic atrophy secondary to age-related macular degeneration with a broad label, the analyst tells investors in a research note. The analyst expects Syfovre to become a blockbuster.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Apellis price target raised to $91 from $86 at Citi
- Apellis rally on approval ‘might fade,’ says Wells Fargo
- Iveric now has ‘clearer path towards approval,’ says BofA
- FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
